MHRA Drug Safety Update: ACE-inhibitors
The product information for all ACE inhibitors is being updated to strengthen the warnings on the risk of delayed-onset angioedema, which may still occur after weeks to years of use. Healthcare professionals, particularly in emergency departments, should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, [...]
The post MHRA Drug Safety Update: ACE-inhibitors appeared first on Community Pharmacy England.
Recent Comments